Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor ...

Investing.com -- Moody’s Ratings has affirmed Eli Lilly and Company ’s Aa3 senior unsecured notes ratings and long-term issuer rating while revising the outlook to positive from stable, the rating ...

A medical expert claims Trump's bruised hand proves he is receiving monthly infusions for possible dementia, linking it to ...

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

As China's aging population increases demand for therapies treating everything from cancer and diabetes to dementia, the ...

China approves 19 innovative drugs for commercial health insurance, opening new market opportunities for global and local ...

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new ...

IBM will reportedly pay $11B for the data streaming company. Lilly, Pfizer, J&J in China’s private insurance catalog. White ...